This report covers the 68 geographical markets and provides an Excel-based forecast model for the Endometriosis market.
Across the 68 markets, sales in the endometriosis market were $1.5 billion in 2024, growing to $4.6 billion in 2034.
The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 37.5% and 45.9% in 68-market sales in 2024 and 2034, respectively.
Across the 68 markets, sales in the endometriosis market were $1.5 billion in 2024, growing to $4.6 billion in 2034.
The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 37.5% and 45.9% in 68-market sales in 2024 and 2034, respectively.
Scope
- This publication is an expanded version of the Excel model containing the patient-based forecast sales for endometriosis, covered in the analyst’s report “Endometriosis: Seven-Market Drug Forecast and Market Analysis to 2034”, published in June 2025. In addition to patient based forecast sales data for the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan), this report contains sales forecast extrapolations for an additional 60 geographical markets (60M), totaling 68 markets (68M).
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 7MM endometriosis therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM endometriosis therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table of Contents
- About the Analyst
1.1 Overview
1.2 68M summary statistics
2 Key 7MM events driving the 68M forecast extrapolation
2.1 Abbreviations
2.2 Methodology
2.3 Primary research - key opinion leaders interviewed for this report
3 Primary research - prescriber survey
2.5 About the authors
- Contact the Publisher
Table 1: Endometriosis market size across the 68M - 7MM versus 61M
Table 2: Endometriosis market size across the 68M - by geographical region
Table 3: Endometriosis, key events occurring in the 7MM driving forecast trajectory in the 68M
Table 4: High-prescribing physicians (non-KOLs) surveyed, by country
List of Figures
Figure 1: Endometriosis market size across the 68M - 7MM versus 61M
Figure 2: Endometriosis market size across the 68M - by geographical region
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbAstraZeneca
- Abbvie
- Debiopharma
- Myovant Science
- Abbott
- Neurocine Biosciences
- Sumitomo
- Ipsen
- Sanofi
- Hope Medicine
- Bayer
- Pfizer
- Kissei
- ASKA Pharmacutical
- Gedeon Richter
